Advanced assay design to compensate for emerging SARS-CoV-2 mutations


In order to provide increased confidence in our COVID-19 test results as SARS-CoV-2 continues to mutate, our TaqPath COVID-19 2.0 tests employ an advanced assay design with increased target redundancy to compensate for both currently known and future SARS-CoV-2 mutations.

Blog series: The Next Generation of COVID-19 Testing

Read now

The new TaqPath assay designs cover three genomic regions and eight total targets.

This design is used across both of our TaqPath COVID-19 2.0 tests.


Product details


TaqPath COVID-19 2.0 test menu details


Internal control

Sample type

Limit of detection

Turnaround time
(sample to result)

Approved sample

Approved system
and software

TaqPath COVID-19 Fast PCR Combo Kit 2.0

Download flyer ›

RNase P

Symptomatic individuals: Raw saliva

750–1,000 GCE/mL*

~2 hours

Lysis (Applied Biosystems
SalivaReady Solution–Assay design,
included in the combo kit)

  • QuantStudio 5 Real-Time PCR System
    (96-well, 0.2 mL)
  • QuantStudio 7 Flex Real-Time PCR System
  • Applied Biosystems Pathogen Interpretive Software (v1.1.0)

TaqPath COVID-19 RNase P Combo Kit 2.0

Download flyer ›

Symptomatic and asymptomatic individuals:

  • Nasopharyngeal swab (NPS)
  • Anterior nasal (nasal) swab

75 GCE/mL LOD*

~3 hours

Thermo Scientific KingFisher
Flex Purification System with

Applied Biosystems MagMAX
Viral/Pathogen II Nucleic Acid Isolation Kit

*LOD of 750 GCE/mL using QuantStudio 7 Flex instrument (384-well); LOD of 1,000 GCE/mL using QuantStudio 5 instrument (96-well, 0.2 mL)




TaqPath COVID-19 2.0 test menu

Thermo Fisher Scientific continues to provide gold standard testing technology with our evolved suite of PCR-based TaqPath COVID-19 2.0 tests, which were developed to help laboratories quickly diagnose COVID-19 caused by SARS-CoV-2 infection. 

Features of the TaqPath COVID-19 2.0 test menu:

  • Same accuracy and reliability you’ve grown to trust—An advanced assay design compensates for current and emerging mutations, helping provide continued confidence in results now and into the future
  • Multiple workflow options—Choose from 3 tests options: two utilize a standard workflow that includes RNA extraction, and the third utilizes a fast, direct-to-PCR workflow with no RNA extraction required
  • Affordable and scalable—Add to your existing COVID-19 test menu using your current real-time PCR instrumentation

Find your IFU

Find the approved Instructions for Use (IFU) for your country. (Note: Product availability varies by country.)

Find out more

For In Vitro Diagnostic Use. Regulatory requirements vary by country. Product may not be available in your geographic region. © 2021 Thermo Fisher Scientific Inc.

All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

Style Sheet for Global Design System
Style Sheet for Komodo Tabs